• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name: leriglitazone
Date Designated: 08/01/2019
Orphan Designation: Treatment of Friedreich´s ataxia
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Minoryx Therapeutics S.L.
TecnoCampus Mataro-Maresme. TCM3 602
Av. Ernest Lluch, 32.
Mataró, Catalunya

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.